Slide 1: 3Q 2016 Financial Results and Business Update
3Q 2016 Financial Results and Business Update November 9th, 2016 Exhibit 99.2
Slide 2: Forward-Looking Statements Safe Harbor Statement
Forward-Looking Statements Safe Harbor Statement Some of the statements made in this presentation are forward-looking statements that involve a number of risks and uncertainties and are made pursuant to the Safe harbor Provisions of the Private Securities Litigation Reform Act of 1995. These forward
Slide 3: Business Update
3Q 2016 Financial Results and Business Update Business Update Geno Germano – President November 9th, 2016
Slide 4: Marketable Products Update: Oxitec and Arctic Apple
Marketable Products Third Quarter 2016 Conference Call: Marketable Products Update Oxitec – Scalable Friendly™ Mosquito solution to suppress the disease-carrying Aedes aegypti Opened large scale facility with capacity to produce ~3 billion mosquitoes annually Began deployments for Brazil expansion a
Slide 5: Marketable Products Update: Trans Ova, Exemplar, AquAdvantage Salmon
Marketable Products Third Quarter 2016 Conference Call: Marketable Products Update Trans Ova – Leader in expanding genetic gains through elite cows Continued cyclical weakness in cattle business impacted 3rd quarter Investing in transitioning to proprietary-product business to drive future growth Ex
Slide 6: Development Platforms: Health Update
Development Platforms: Health Third Quarter 2016 Conference Call: Development Platforms Update Oncology: Collaborator ZIOPHARM will provide update on Ad-RTS-IL-12 Phase I trial for recurrent glioblastoma at Society for Neuro-oncology Conference in November ZIOPHARM has requested meeting with FDA at
Slide 7: Development Platforms: Rare Diseases and Ophthalmology
Development Platforms: Health Third Quarter 2016 Conference Call: Development Platforms Update Rare Diseases: FCX-007, a gene therapy engineered for the ultra-orphan indication of Recessive Dystrophic Epidermolysis Bullosa or RDEB, has entered clinical stage Collaborator Fibrocell has completed enro
Slide 8: Clinical Trials Utilizing Intrexon Technologies
Development Platforms: Health 4 Clinical Trials Utilizing Intrexon Technologies Up to 11 Clinical Trials or INDs Utilizing Intrexon Technologies 12 Additional Programs in Current Pipeline Utilizing Intrexon Technologies Q3 2016 Q2 2017 After Q2 2017 Third Quarter 2016 Conference Call: Development Pl
Slide 9: Health Pipeline
Health Pipeline* *Not complete list Third Quarter 2016 Conference Call: Development Platforms Update
Slide 10: Development Platforms: Energy & Chemicals
Development Platforms: Energy & Chemicals Methanotroph Major yield advantage projected over other bio-based approaches Our platform utilizes natural gas as its feedstock Natural gas is inexpensive source of carbon on a $/MBTU basis Fermentation Natural gas Third Quarter 2016 Conference Call: Develop
Slide 11: Development Platforms: Crop Protection
Development Platforms: Crop Protection Intrexon Crop Protection (ICP) offers precision pest control with limited environmental impact, potential for superior efficacy, and avoidance of insect resistance utilizing two platforms: ActoBiotics® platform and Oxitec’s self-limiting species-specific insect
Slide 12: Financial Review
3Q 2016 Financial Results and Business Update Financial Review Joel Liffmann – SVP, Finance November 9th, 2016
Slide 13: Third Quarter Financial Performance
Third Quarter Financial Performance * Non-GAAP financial measure as previously defined. ** Non-GAAP financial measure as redefined. Select Financial Highlights 3Q 2016 3Q 2015 Revenues $49.0 M $53.4 M Collaboration and Licensing Revenues $30.6M $34.7M Product & Services and Other Revenues $18.4M $18
Slide 14: Financial Discipline
Financial Discipline We target at least 100% coverage of Annual Cash Operating Expenses as we build significant portfolio of backend commercial economics FY 2014 111% þ FY 2015 133% þ Q3 2016 80% þ YTD 2016 150% þ *Cash consideration received for reimbursement of R&D services; **Total consideration
Slide 15: Portfolio Expansion & Maturation
Portfolio Expansion & Maturation September 2016 1 Over 30 January 2011 Collaborations September 2016 $17.5MM $391 Million January 2011 TAF and Received Milestones September 2016 $0 $176 Million January 2011 Cost Recovery Portfolio of Backend Economics Future Milestones & Royalties Third Quarter 2016
Slide 16: Summary
Summary Over 30 collaborations in place capitalizing on our leadership position in the engineering of biology Strong cash position with $280.7 million in cash, cash equivalents, and short and long-term investments, and equity securities and preferred stock valued at $163 million Developing high valu
Slide 17: Q&A Session
3Q 2016 Financial Results and Business Update Q&A Session November 9th, 2016
Slide 18: Appendix: Adjusted EBITDA and Adjusted EBITDA per share
Appendix Adjusted EBITDA and Adjusted EBITDA per share. To supplement Intrexon’s financial information presented in accordance with U.S. generally accepted accounting principles (“GAAP”), Intrexon presents Adjusted EBITDA and Adjusted EBITDA per share. Beginning this quarter, the Company redefined t
Slide 19: Appendix: Reconciliation of Net Loss to Adjusted EBITDA
Appendix The following table presents a reconciliation of net income (loss) attributable to Intrexon to EBITDA and also to Adjusted EBITDA, as well as the calculation of Adjusted EBITDA per share, for each of the periods indicated: Three months ended Nine months ended September 30, September 30, 201
Slide 20: Appendix: Reconciliation of Redefined Non-GAAP Measures
Appendix The following table reconciles the revised and previously defined Adjusted EBITDA measures in the current and prior periods. Going forward, the Company will no longer present Adjusted EBITDA based on the previous definition. However, supplemental information about the impact of the change i